What's in BioAtla, Inc.'s pipeline?

BioAtla, Inc. has 4 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 3 in Phase 1.

Which companies overlap with BioAtla, Inc.'s portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, AstraZeneca, Byondis B.V., Charite University, Berlin, Germany, Gustave Roussy, Cancer Campus, Grand Paris.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bioatla-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

BioAtla, Inc. — Portfolio Competitive Intelligence Brief

BioAtla, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 1 shared drug class
AstraZeneca · 1 shared drug class
Byondis B.V. · 1 shared drug class
Charite University, Berlin, Germany · 1 shared drug class
Gustave Roussy, Cancer Campus, Grand Paris · 1 shared drug class
Jiaxing AnDiCon Biotech Co.,Ltd · 1 shared drug class
Medstar Health Research Institute · 1 shared drug class
Amgen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BioAtla, Inc.:

Cite this brief

Drug Landscape (2026). BioAtla, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioatla-inc. Accessed 2026-05-14.